Goldman Sachs Downgrades Intercept Pharmaceuticals (ICPT) to Neutral, After Receiveing Complete Response Letter From FDA
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals (NASDAQ: ICPT) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
